InMed Pharmaceuticals Inc. (INM)
| Market Cap | 1.76M |
| Revenue (ttm) | 5.49M |
| Net Income (ttm) | -6.35M |
| Shares Out | 6.06M |
| EPS (ttm) | -1.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58,855 |
| Open | 0.291 |
| Previous Close | 0.301 |
| Day's Range | 0.270 - 0.300 |
| 52-Week Range | 0.262 - 2.080 |
| Beta | 0.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2024 |
About INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with hi... [Read more]
Financial Performance
In 2023, INM's revenue was $4.14 million, an increase of 279.61% compared to the previous year's $1.09 million. Losses were -$7.95 million, -57.27% less than in 2022.
Financial StatementsNews
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commerci...
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical d...
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathway In Vivo studies demonstrate INM-901 reduces neuroinflammation and improves n...
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization o...
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
Advancing two new preclinical programs in Alzheimer's and Age-Related Macular Degeneration Closed calendar year 2023 with cash position of US$9.5 million 164% revenue growth in the commercial BayMedic...
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization...
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization...
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
Advancing INM-901 as a multimodal treatment option for Alzheimer's Disease Advancing INM-089 in the treatment of Age-related Macular Degeneration Actively seeking partnerships to advance INM-755 in De...
InMed Announces Results of 2023 Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufa...
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufactu...
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufactur...
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufactur...
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufactur...
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies
In vitro Alzheimer's disease studies show that INM-901 treated groups display neuroprotection and extended neurite length, a potential marker for improved neuronal function INM-901 treated groups in a...
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
Completed Phase 2 Clinical Trial demonstrating anti-itch activity of INM-755 (CBN) topical cream $4.1M revenues in fiscal year 2023, representing a 280% increase over the previous fiscal year and $2.3...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufact...
InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 7, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufactu...
InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing...
InMed Provides Update on BayMedica Rare Cannabinoid Business
$2.3M revenues (unaudited) in Q4 2023, representing 123% increase quarter over quarter ("QoQ") Optimized and scaled up manufacturing processes over the last 12 months to meet increasing demand Third c...
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa
An exploratory clinical evaluation of the Phase 2 clinical trial data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol ("CBN") cream versus the control cream alone. T...
InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing ...
InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET
Vancouver, British Columbia--(Newsfile Corp. - May 18, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing ...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
Completed enrollment in Phase 2 Clinical Trial; data readout expected during calendar 3Q 2023 120% quarter-over-quarter revenue growth in the commercial BayMedica subsidiary Published a peer-reviewed ...
InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
Marks the first time a Phase 2 trial has studied a cannabinol (CBN) formulation as a treatment option for any disease Data expected to be released in early calendar Q3 2023 Vancouver, British Columbia...
InMed to Participate in Upcoming Investor Events
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufactur...